Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. - Wikidata - wikimedia - TriplyDB

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

http://www.wikidata.org/entity/Q34820655

about

Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein.Reverse Genetics Approaches for the Development of Influenza Vaccines Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon Influenza A and B virus intertypic reassortment through compatible viral packaging signals.PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets.A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner.Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza-associated mortality among the elderly.Innate immune evasion strategies of influenza viruses Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.Development of an Alternative Modified Live Influenza B Virus Vaccine.The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein.Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.Identification of small molecules with type I interferon inducing properties by high-throughput screening.Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.Animal Models for Influenza Virus Pathogenesis and Transmission.Replication-competent influenza A viruses expressing a red fluorescent protein.Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates Transmission of influenza B viruses in the guinea pig.Replication-Competent Influenza A and B Viruses Expressing a Fluorescent Dynamic Timer Protein for In Vitro and In Vivo Studies.Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response.Incoming influenza A virus evades early host recognition, while influenza B virus induces interferon expression directly upon entry.NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies Arenavirus reverse genetics for vaccine development Blocking interhost transmission of influenza virus by vaccination in the guinea pig model.NS1 Protein Mutation I64T Affects Interferon Responses and Virulence of Circulating H3N2 Human Influenza A Viruses.Animal models for the study of influenza pathogenesis and therapy.Viral tricks to grid-lock the type I interferon system.Immunomodulatory therapy for severe influenza.Inhibition of the type I interferon antiviral response during arenavirus infection.

P2860

Q26745547-EFEDDAD8-0958-4C57-A577-CEAABDDB6C00 Q27316764-0AC7A3F5-1E0D-4A45-80B2-DC4150305970 Q27865245-FFB1DD1C-9699-4E83-B0ED-95736F3AE1ED Q28076140-431F5CA5-ACA6-4CAC-A5EB-9E3FB98D42F9 Q28395006-7E0235A4-D308-4EE9-9EE4-09E5186C8A63 Q28483298-2FD38148-4D8C-42F1-962F-26CDF1D75F75 Q30364518-34013949-0F8E-4383-AB4B-614B5A21AD30 Q30385984-83962634-94B8-4B3A-86C1-8A78AF312C1E Q30400777-D2924EED-8BA6-4E70-8286-19746DE04BC2 Q30402334-AB47E2C5-0260-4600-BB8A-7A5E86F7C621 Q30412616-9540C37F-5CC4-4444-A30A-F71A22CB5782 Q30423962-DECF35F1-DFB1-4F73-9F84-ED7AC72F61FA Q30429134-69B5097C-D7F1-41FB-9079-2E6F86AE8454 Q30474419-9923433E-6432-41E3-83B7-DD63E49D520A Q33622358-2740D998-11F4-4805-B054-D7EAA81E00E2 Q33646273-7A5996E3-ACB3-43EB-A2C0-0E458E89BA53 Q33653692-E441B437-BCAC-4740-804F-8C8806CB3B3B Q33733453-7F77E77D-ADEC-4FFB-95CC-4500B58BFDBD Q33939684-C2143917-B6BC-494F-9ECE-629F55B27ECE Q34101229-B0C0CA87-1A7E-49AE-9223-48E5C80839AB Q34473943-819125CA-2509-4CCF-928E-91F78FBD23A3 Q34511080-FC588F75-B5A8-4B05-92B5-7C2A59FDE02B Q34714853-4EF65F0F-41DA-48BD-9AAD-52BE7676850B Q35071285-B7333C3D-F5BF-4221-A011-72E25D9E5E3A Q35076577-4648776C-B124-42E2-8C2C-BCA68A0740D8 Q35868018-12EA3ED8-DE42-4F24-8F01-79572B0ACFE3 Q35904047-5735C339-A3F9-4EE0-9CE6-E33AAFEC1A89 Q35943392-9678165D-532B-449A-968E-973E8F2F98D0 Q36005999-EDB78D20-ADF2-4BDB-9386-941DFCFAD3FF Q36276192-56107FA7-9E3C-463D-9F45-DBC7B4D0D6FF Q36276683-658EABDE-8A10-4502-9582-5796817DC59E Q36281137-D8D6815F-AEDD-42F3-908A-94C0479EC6B6 Q36911722-F671FBFA-79DF-46DF-BF0C-E5B7394AE1B0 Q37006773-E13E9137-1096-4F4E-80B4-F4BD495ADBAC Q37127910-A74D4D3C-A79B-441C-B625-1DDCD039E3C2 Q37347309-05370A7D-06F0-4FA4-AEA5-CF5DB8FAA047 Q37379466-F317B2A2-F2FD-4656-AE40-F73CB9A79764 Q37764230-61C11215-848F-4DF5-BB98-B3332D1E8192 Q37910249-DE1E53A1-125E-4864-B36A-79128C16DBAD Q37945195-A93E8A58-693F-48E5-84AF-9C26A52A4F40

P2860

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

http://www.wikidata.org/entity/Q34820655

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@ast

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@en

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@nl

type

label

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@ast

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@en

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@nl

prefLabel

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@ast

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@en

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@nl

P1433

Q34820655-82FD2E80-5F86-404E-BBFE-3AAA911511E1

P1476

Q34820655-CD285206-FA97-4508-BFDE-66469A4BD511

P2093

Q34820655-6AE376E9-1D37-4937-AE2F-B41D388F2FFB

Q34820655-AD1B2217-8853-4404-B11B-AD1B8E4A1F10

Q34820655-D5D39C51-C59A-44D6-A4E2-2AB870488B1B

P2860

Q34820655-1122D3CA-D2F8-4C1D-B851-9775E331FADA

Q34820655-1647C0A1-ABBD-4EA0-B1A1-841397FC52E8

Q34820655-1DEE8246-1446-4C30-9BBE-A3C94D50DF21

Q34820655-1F18EBD5-939E-4C1C-931F-29369826F7F8

Q34820655-221B8585-3277-4EE4-B553-47B034C1F640

Q34820655-32D8A35E-90A3-48B0-9A97-EC1182C93DBB

Q34820655-33F472C5-9A6F-4B28-AF2E-4893F2C53B53

Q34820655-40127E09-C42A-459F-8A1C-8FA5BF340405

Q34820655-40FF8D96-B626-4ECF-BCDF-59A5D4A9ED07

Q34820655-54F74F4A-FD27-48EA-BA77-712D400243F6

P304

Q34820655-3217FDF3-382C-4BA0-9C70-570054E6EC17

P31

Q34820655-C53D30F0-2540-49DC-A483-73CDD7087A99

P356

Q34820655-8BC7D112-2F19-4052-9D28-75CE9358E89F

P407

Q34820655-541EDFED-9EE5-4E49-96DF-48FB678956D6

P433

Q34820655-BE513049-2C33-42B9-96A9-352137E44C21

P478

Q34820655-693B4F18-899F-4C6E-882B-01921E11FAA7

P50

Q34820655-31E37046-FBC9-421E-901D-917BE60CF904

Q34820655-3BB8EE92-3CF6-4843-AB83-84CB96041E10

Q34820655-42C98C6E-EFEE-4A4D-AE7A-6862A2C6FDFE

P577

Q34820655-A8517F90-6109-4A6C-90B8-FD0032B9E0EF

P698

Q34820655-AA797B73-7569-494E-AA47-6A5AACC4E874

P921

Q34820655-9AE5814E-BC0E-4DBD-AA10-C1B857ADE708

P932

Q34820655-59BE67BC-1A57-41F5-A5F7-75663FCBC02A

P356

P1433

Journal of Virology

P1476

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

@en

P2093

Juan Ayllon

http://www.w3.org/2001/XMLSchema#string

Kathryn A Fraser

http://www.w3.org/2001/XMLSchema#string

Rong Hai

http://www.w3.org/2001/XMLSchema#string

P2860

Influenza B Virus in Seals

Making better influenza virus vaccines?

Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein

Comparison of the mutation rates of human influenza A and B viruses

Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses

Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication.

A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice

Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems

Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase

Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature.

P304

10580-10590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01213-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Adolfo García-Sastre

Luis Martinez-Sobrido

P577

2008-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18768976

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

2573209

http://www.w3.org/2001/XMLSchema#string